Category: COVID19

PAXLOVID® (nirmatrelvir tablets and ritonavir tablets) will be available on the Pharmaceutical Benefits Scheme (PBS) to people between 50–59 years with mild to moderate COVID-19, with one additional risk factor from 1 July 2023. Wider eligibility criteria mean more Australians most at risk of severe disease may be able to access PBS-subsidised PAXLOVID if they … Continued

  PAXLOVID® (nirmatrelvir tablets and ritonavir tablets) will be available on the Pharmaceutical Benefits Scheme (PBS) to people between 50–59 years with mild to moderate COVID-19, with one additional risk factor from 1 July 2023. Wider eligibility criteria mean more Australians most at risk of severe disease may be able to access PBS-subsidised PAXLOVID if … Continued

New research shows Australians increasingly report being less likely to take protective measures or act if they suspect they have COVID-19. Over 60s show significant concern about COVID-19, despite 3 in 5 being unaware of their potential eligibility for anti-virals.1 Australians urged to renew their COVID-safe behaviours to help protect their communities.   SYDNEY, AUSTRALIA, … Continued